Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Ian Neil Fleming; Morag Hogben; Sheelagh Frame; Steven J McClue; Simon R Green

doi:10.1158/1078-0432.CCR-07-4633

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Ian Neil Fleming, Morag Hogben, Sheelagh Frame, Steven J McClue, Simon R Green

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

Original language	English
Pages (from-to)	4326-4335
Number of pages	10
Journal	Clinical Cancer Research
Volume	14
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.CCR-07-4633
Publication status	Published - 2008

Keywords

Animals
Antineoplastic Agents
Cell Line, Tumor
Cyclin D1
Drug Synergism
Female
Gene Expression Regulation, Neoplastic
Humans
Inhibitory Concentration 50
Mice
Models, Biological
Mutation
Neoplasm Transplantation
Purines
Receptor, erbB-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-07-4633

Cite this

@article{f54e4584315c4945b73ec81654f807fc,

title = "Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents",

abstract = "The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.",

keywords = "Animals, Antineoplastic Agents, Cell Line, Tumor, Cyclin D1, Drug Synergism, Female, Gene Expression Regulation, Neoplastic, Humans, Inhibitory Concentration 50, Mice, Models, Biological, Mutation, Neoplasm Transplantation, Purines, Receptor, erbB-2",

author = "Fleming, {Ian Neil} and Morag Hogben and Sheelagh Frame and McClue, {Steven J} and Green, {Simon R}",

year = "2008",

doi = "10.1158/1078-0432.CCR-07-4633",

language = "English",

volume = "14",

pages = "4326--4335",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

AU - Fleming, Ian Neil

AU - Hogben, Morag

AU - Frame, Sheelagh

AU - McClue, Steven J

AU - Green, Simon R

PY - 2008

Y1 - 2008

N2 - The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

AB - The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

KW - Animals

KW - Antineoplastic Agents

KW - Cell Line, Tumor

KW - Cyclin D1

KW - Drug Synergism

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Inhibitory Concentration 50

KW - Mice

KW - Models, Biological

KW - Mutation

KW - Neoplasm Transplantation

KW - Purines

KW - Receptor, erbB-2

U2 - 10.1158/1078-0432.CCR-07-4633

DO - 10.1158/1078-0432.CCR-07-4633

M3 - Article

C2 - 18594016

SN - 1078-0432

VL - 14

SP - 4326

EP - 4335

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 13

ER -

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this